HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma.

AuthorsSaurabh Zanwar, Matthew Ho, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Dingli, Taxiarchis Kourelis, Amie Fonder, Miriam Hobbs, Yi Hwa, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Robert A Kyle, S Vincent Rajkumar, Shaji Kumar
JournalLeukemia (Leukemia) Vol. 36 Issue 3 Pg. 873-876 (03 2022) ISSN: 1476-5551 [Electronic] England
PMID34635783 (Publication Type: Letter)
Chemical References
  • Antineoplastic Agents, Immunological
  • Immunomodulating Agents
  • Proteasome Inhibitors
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Immunological (therapeutic use)
  • Female
  • Follow-Up Studies
  • Humans
  • Immunomodulating Agents (therapeutic use)
  • Male
  • Middle Aged
  • Multiple Myeloma (diagnosis, drug therapy)
  • Proteasome Inhibitors (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: